Literature DB >> 30109003

Structure and properties of DOTA-chelated radiopharmaceuticals within the 225Ac decay pathway.

Artem R Khabibullin1, Aleksandra Karolak2, Mikalai M Budzevich3, Mark L McLaughlin4, David L Morse5,6, Lilia M Woods1.   

Abstract

The successful delivery of toxic cargo directly to tumor cells is of primary importance in targeted (α) particle therapy. Complexes of radioactive atoms with the 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelating agent are considered as effective materials for such delivery processes. The DOTA chelator displays high affinity to radioactive metal isotopes and retains this capability after conjugation to tumor targeting moieties. Although the α-decay chains are well defined for many isotopes, the stability of chelations during the decay process and the impact of released energy on their structures remain unknown. The radioactive isotope 225Ac is an α-particle emitter that can be easily chelated by DOTA. However, 225Ac has a complex decay chain with four α-particle emissions during decay of each radionuclide. To advance our fundamental understanding of the consequences of α-decay on the stability of tumor-targeted 225Ac-DOTA conjugate radiopharmaceuticals, we performed first principles calculations of the structure, stability, and electronic properties of the DOTA chelator to the 225Ac radioactive isotope, and the initial daughters in the decay chain, 225Ac, 221Fr, 217At and 213Bi. Our calculations show that the atomic positions, binding energies, and electron localization functions are affected by the interplay between spin-orbit coupling, weak dispersive interactions, and environmental factors. Future empirical measurements may be guided and interpreted in light of these results.

Entities:  

Year:  2018        PMID: 30109003      PMCID: PMC6072494          DOI: 10.1039/c8md00170g

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  32 in total

1.  Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use.

Authors:  D Ma; M R McDevitt; R D Finn; D A Scheinberg
Journal:  Appl Radiat Isot       Date:  2001-11       Impact factor: 1.513

2.  Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.

Authors:  Hong Song; Robert F Hobbs; Ravy Vajravelu; David L Huso; Caroline Esaias; Christos Apostolidis; Alfred Morgenstern; George Sgouros
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

Review 3.  Radioimmunotherapy with alpha-emitting nuclides.

Authors:  M R McDevitt; G Sgouros; R D Finn; J L Humm; J G Jurcic; S M Larson; D A Scheinberg
Journal:  Eur J Nucl Med       Date:  1998-09

4.  Projector augmented-wave method.

Authors: 
Journal:  Phys Rev B Condens Matter       Date:  1994-12-15

5.  Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes.

Authors:  Justin J Wilson; Maryline Ferrier; Valery Radchenko; Joel R Maassen; Jonathan W Engle; Enrique R Batista; Richard L Martin; Francois M Nortier; Michael E Fassbender; Kevin D John; Eva R Birnbaum
Journal:  Nucl Med Biol       Date:  2014-12-20       Impact factor: 2.408

6.  Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.

Authors:  Matthias Miederer; Michael R McDevitt; Paul Borchardt; Ira Bergman; Kim Kramer; Nai-Kong V Cheung; David A Scheinberg
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

7.  Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.

Authors:  Markus Essler; Florian C Gärtner; Frauke Neff; Birgit Blechert; Reingard Senekowitsch-Schmidtke; Frank Bruchertseifer; Alfred Morgenstern; Christof Seidl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-12       Impact factor: 9.236

8.  Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.

Authors:  Matthias Miederer; Michael R McDevitt; George Sgouros; Kim Kramer; Nai-Kong V Cheung; David A Scheinberg
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

9.  Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.

Authors:  Matthias Miederer; Gjermund Henriksen; Andrea Alke; Ilona Mossbrugger; Leticia Quintanilla-Martinez; Reingard Senekowitsch-Schmidtke; Markus Essler
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

Review 10.  Dissemination and growth of cancer cells in metastatic sites.

Authors:  Ann F Chambers; Alan C Groom; Ian C MacDonald
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

View more
  3 in total

1.  Theoretical Study of Actinide(III)-DOTA Complexes.

Authors:  Attila Kovács
Journal:  ACS Omega       Date:  2021-05-11

Review 2.  Atomic Nanogenerators in Targeted Alpha Therapies: Curie's Legacy in Modern Cancer Management.

Authors:  Mareike Roscher; Gábor Bakos; Martina Benešová
Journal:  Pharmaceuticals (Basel)       Date:  2020-04-23

Review 3.  Development of Targeted Alpha Particle Therapy for Solid Tumors.

Authors:  Narges K Tafreshi; Michael L Doligalski; Christopher J Tichacek; Darpan N Pandya; Mikalai M Budzevich; Ghassan El-Haddad; Nikhil I Khushalani; Eduardo G Moros; Mark L McLaughlin; Thaddeus J Wadas; David L Morse
Journal:  Molecules       Date:  2019-11-26       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.